Key result
In patients with heart failure and reduced ejection fraction, ivabradine reduces cardiovascular mortality by 17%, heart failure mortality by 39%, and heart failure hospitalization by 30%.
Why the study?
Does ivabradine reduce cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate?
Does ivabradine reduce cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate?
Ivabradine is an effective treatment for reducing cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate despite beta-blocker therapy.
Answers are grounded in this paper and cite their sources.
May support ivabradine consideration in HFrEF; leaves open definitive efficacy confirmation in RCTs.
A high resting heart rate (≥70–75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not only reduce heart rate but also have negative inotropic and blood pressure-lowering effects, and therefore, in many patients, they cannot be given in the recommended dose. Ivabradine specifically inhibits the pacemaker current (funny current, I f ) of the sinoatrial node cells, resulting in therapeutic heart rate lowering without any negative inotropic and blood pressure-lowering effect. According to the European Society of Cardiology guidelines, ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with a reduced left ventricular EF ≤35% and sinus rhythm ≥70 b.p.m. despite treatment with an evidence-based dose of beta-blocker or a dose below the recommended dose (recommendation class “IIa” = weight of evidence/opinion is in favor of usefulness/efficacy: “should be considered”; level of evidence “B” = data derived from a single randomized clinical trial or large nonrandomized studies). Using a heart rate cutoff of ≥ 75 b.p.m., as licensed by the European Medicines Agency, treatment with ivabradine 5–7.5 mg b.i.d. reduces cardiovascular mortality by 17%, HF mortality by 39% and HF hospitalization rate by 30%. A high resting heart rate is not only a risk factor in HF with reduced EF but also at least a risk marker in HF with preserved EF, in acute HF and also in special forms of HF. In this review, we discuss the proven role of ivabradine in the validated indication “HF with reduced EF” together with interesting preliminary findings, and the potential role of ivabradine in further, specific forms of HF.
No takes yet. Share an insight, caveat, or question.
Müller‐Werdan et al. (2016) conducted a review in Heart failure with reduced ejection fraction. Ivabradine was evaluated. In patients with heart failure and reduced ejection fraction, ivabradine reduces cardiovascular mortality by 17%, heart failure mortality by 39%, and heart failure hospitalization by 30%.
Synapse has enriched 10 related papers. Consider them for comparative context: